REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Napatree Capital LLC

Napatree Capital LLC lowered its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 33,525 shares of the biotechnology company’s stock after selling 1,600 shares during the period. Napatree Capital LLC owned about 0.07% of REGENXBIO worth $259,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in RGNX. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in REGENXBIO during the third quarter worth about $643,000. Intech Investment Management LLC purchased a new stake in REGENXBIO during the third quarter worth about $161,000. Charles Schwab Investment Management Inc. boosted its holdings in REGENXBIO by 9.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock worth $4,382,000 after buying an additional 37,055 shares in the last quarter. FMR LLC boosted its holdings in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock valued at $214,000 after purchasing an additional 17,533 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Morgan Stanley upped their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, March 14th. Raymond James assumed coverage on shares of REGENXBIO in a report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Thursday. HC Wainwright reduced their price target on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, REGENXBIO has an average rating of “Moderate Buy” and an average target price of $33.88.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $8.24 on Monday. REGENXBIO Inc. has a one year low of $5.62 and a one year high of $22.42. The company has a 50 day moving average price of $7.30 and a 200 day moving average price of $8.87. The firm has a market capitalization of $412.71 million, a price-to-earnings ratio of -1.64 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. As a group, equities analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.